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Abstract The selective and efficient drug delivery to tumor 
cells can remarkably improve different cancer therapeutic ap­
proaches. There are several nanoparticles (NPs) which can act 
as a potent drug carrier for cancer therapy. However, the spe­
cific drug delivery to cancer cells is an important issue which 
should be considered before designing new NPs for in vivo 
application. It has been shown that cancer cells over-express 
folate receptor (FR) in order to improve their growth. As nor­
mal cells express a significantly lower levels of FR compared 
to tumor cells, it seems that folate molecules can be used as 
potent targeting moieties in different nanocarrier-based 
therapeutic approaches. Moreover, there is evidence 
which implies folate-conjugated NPs can selectively de­
liver anti-tumor drugs into cancer cells both in vitro and 
in vivo. In this review, we will discuss about the effi­
ciency of different folate-conjugated NPs in cancer 
therapy. 
Keywords Folate . Folate receptor . Nanoparticle . Cancer 
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Introduction 
Nanomedicine is a recent expanded novel technology, with 
various advantages for diagnosis and treatment of several dis­
orders such as autoimmunity and cancer. Since the current 
therapeutic methods are usually ineffective for cancer, it 
seems that the identification of novel methods, which are safe 
and effective, is required [1]. Surgery, radiation, and chemo­
therapy are conventional tumor therapeutic approaches, which 
destruct both tumor and normal cells. As nanoscale therapeu­
tic materials demonstrate several features such as nontoxic, 
biodegradable, non-immunogenic, biocompatible, and gradu­
al long-time drug release, they can be considered as potent 
candidates in cancer therapy [2]. It has been shown that nano­
particles (NPs) can be applied for various purposes, including 
drug delivery, diagnosis, and regenerative medicine. NPs can 
act as worthy drug carriers, which is in part due to their unique 
properties such as protection of drugs against degradation in 
the circulation before they reach their target site, promotion of 
drug absorption in cancer cells and tissues, and gradual drug 
release [3]. 
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As mentioned, non-specific action of common anti-cancer 
drugs leads to destruction of both tumor and normal cells. 
Thus, targeted cancer therapy can increase the efficiency of 
current therapeutic approaches. Consistently, modification of 
different NPs for specific targeting is of great importance for a 
targeted therapy [4]. There are two general targeting methods, 
including passive and active targeting approaches. The unique 
physiologic properties of tumor microenvironment and phys­
icochemical features of NPs facilitate the preferred accumula­
tion of nanocarriers in tumor tissues. This is the main objective 
of passive targeting. In spite of preferred accumulation of 
nanocarriers through passive mechanisms, there is some de­
gree of non-specific action in this method. Moreover, passive 
targeting does not guarantee the cellular uptake of drug-loaded 
NPs. Furthermore, although the passively targeted NPs can 
accumulate within the tumor site, they can also diffuse out 
of the tumor region and back into the blood circulation. 
Active targeting approaches can significantly decrease the 
non-specific action of passively targeted nanocarriers. Active 
targeting can be performed through surface conjugation of 
nanocarriers to various targeting molecules such as antibodies 
against tumor markers, aptamers, carbohydrates, vitamins and 
peptides or ligands of some overexpressed molecules on tu­
mor cells such as transferrin and folate (vitamin B9) [5]. It has 
been reported that folate receptor (FR) is overexpressed on the 
surface of several cancers, including breast, kidney, lung, 
brain, and ovary cancers [6]. Folate can bind to FR and facil­
itate the transfer of folate-targeted NPs through receptor­
mediated endocytosis. Folic acid is an essential nutrient need­
ed by all cells for biosynthesis of nucleotide and normal action 
of some metabolic pathways. It has been shown that FR has 
high affinity (Kd»10−10 M) for the folic acid (FA) [7] and 
mediates the cellular uptake via a non-destructive [6], 
endosomal pathway [3]. Regarding the limited expres­
sion of FR on normal tissues and its overexpression 
on tumor cells [6], it seems that folate may be an ap­
propriate choice for targeting tumor cells in NP-based 
cancer therapies. FR can internalize its ligand into the 
cytosol, because it is linked to the lipid region of the 
cell membrane. Following migration of FR and its con­
tents to inner side of membrane, the acidic microenvi­
ronment of interior side (pH of approximately 5) leads 
to dissociation of FR from the folate-conjugated NPs. 
Thus, folate-conjugated NPs can then release into the 
cytosol of the tumor cells following migration to the 
interior surface of the cell membrane (Fig. 1) [7]. As 
mentioned, folate-targeting can effectively increase the 
efficiency of cancer therapy, as several tumor cells 
over-express FR on their surface. Consistently, several 
drugs have conducted toward tumor tissues through var­
ious FA-conjugated NPs (Fig. 2) [8]. In here, we sum­
marize the recent advances regarding the use of folate­
conjugated NPs in cancer therapy. 
Polymeric micelles 
Polymeric micelles are nanosized core/shell particles constitut­
ed by amphiphilic block copolymers [9]. The hydrophilic shell 
of the micelle increases its circulation time in the body and 
inhibits its uptake by the mononuclear phagocyte system [10]. 
Micelles with a size range of 5–100 nm have the inner hydro­
phobic core, which enables them to engulf poorly water-soluble 
drugs [9]. Polyesters, polyethers, and polyamino acids are com­
monly used polymers for hydrophobic core of micelles [11]. 
Polymeric micelles possess several strong advantages, such as 
their physicochemical properties for tumor targeting by a pas­
sive targeting mechanism called the enhanced permeability and 
retention effect [12]. For targeting the tumor at inaccessible 
sites, the drug should be administered by the parenteral route, 
and pharmaceutical drug carriers carrying drug in plasma 
should possess properties like biodegradability, small particle 
size, high loading capacity, prolonged circulation, and accumu­
lation in the required pathological site in the body [12]. 
Compared with other drug carriers, micelles have the advantage 
because of their very small size, which is critical for passive 
targeting to solid tumors, particularly the poorly vascularized 
tumors. Micelles have demonstrated a variety of shapes such as 
spheres, rods, vesicles, tubules, and lamellae, which lead to a  
significant impact on the pharmacokinetic properties of mi­
celles [13]. These nanocarriers can act as potent drug reservoirs 
and are able to provide the high concentrations of the drug in 
tumor tissues. Micelles are mainly applied for drug solubiliza­
tion, controlled drug release, and drug targeting [13]. Drug 
release from micelles at target site can be managed through 
various mechanisms such as pH-, thermo-, ultrasound-, and 
light-sensitivity [14, 15]. 
It is demonstrated that folate conjugation can increase the 
stability of FA-poly(ethylene glycol) (PTL-PLA-MPEG/ 
PEG-FA) micelle compared to poly(L-lactic acid)-block­
methoxy poly(ethylene glycol) copolymer (PLA-MPEG), 
which was in part due to the lower micelle concentration 
[16]. Similarly, it is reported that FA-conjugated doxorubicin 
(DOX)-loaded PLA-PEG-based polymeric micelles exhibit a 
potent cytotoxicity against FR-expressing SKOV3 human 
ovarian cancer cells, in vitro [17]. 
FA-conjugated micelles have been shown to exert potent 
anti-tumor effect both in vitro and in vivo. Scarano and col­
leagues have shown that both small and large FA-conjugated 
micelles loaded with platinum drugs exert higher anti-tumor 
effects on FR-expressing cell line OVCAR-3 compared to FR­
negative A549 cells [18]. In another study, Gao et al. showed 
the inhibition of tumor cells metastasis in 4T1 tumor-bearing 
mice by DOX-loaded FA-targeted pH-sensitive polymeric mi­
celles. FA-conjugated micelles could effectively inhibit tumor 
growth and metastasis and increase mice survival [14]. Gue 
et al. have also showed that DOX-conjugated FA-conjugated 
PEG-poly(ε-caprolactone) micelles exert potent anti-tumor 
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Fig. 1 The representative schematic platform for site-specific drug 
delivery through folate-conjugated pH-sensitive NPs. Folate-targeted 
NPs reach and bind to tumor cells with high affinity due to the 
overexpression of folate receptors on tumor cells. Tumor cells take 
these multifunctional NPs via FR-mediated endocytosis mechanism, by 
which these nanocarriers enter into the endosomal vesicles in which they 
are exposed to an acidic microenvironment. In the acidic pH of 
function in both in vitro and in vivo. In this nanoformulation, 
DOX was connected with a hydrazone linker (FA-hyd) for a 
pH-mediated drug release. They demonstrated that FA-hyd 
micelles had significantly more circulation time and enriched 
drug into the tumors rather than normal tissues [19]. The sim­
ilar results were reached in another investigation using two 
series of FA-targeted pH-sensitive amphiphilic block copoly­
mers, poly(ε-caprolactone)-b-poly[triethylene glycol methac­
rylate-co-N-methacryloyl  caproic  acid]  and poly(ε­
caprolactone)-b-poly[triethylene glycol methacrylate-co­
N-(2-(methacrylamido)ethyl] in vitro in FR-positive (HeLa) 
and FR-negative (HT-29) tumor cell lines [20]. There are other 
reports, which applied pH-dependent drug release approach 
for the control of tumor growth in FA-targeted micelles. For 
example, while Bae et al. used FA-PEG-poly(aspartate 
hydrazone adriamycin) [FA-PEG-P(Asp-Hyd-ADR)] to stop 
the growth of human pharyngeal cancer cells (KB cell) in vitro 
[21], Liu and coworkers developed DOX-loaded poly(N­
isopropylacrylamide-co-N,N-dimethylacrylamide-co-2­
aminoethyl methacrylate)-b-poly(10-undecenoic acid) 
(P(NIPAAm-co-DMAAm-co-AMA)-b-PUA) micelles in or­
der to attenuate tumor burden in 4T1 tumor-bearing mice 
and KB cells [22]. Song and colleagues developed redox­
and pH-sensitive FA-targeted DOX-loaded polyurethane 
nanomicelles, which controlled the growth of FR-positive 
HeLa cells in vitro [23]. 
In addition to pH-sensitive NPs, thermosensitive FA-
conjugated micelles are also developed, which showed good 
endosomes (or  cytoplasm),  NPs  release  encapsulated drug  
(doxorubicin) and kill cancer cell. Drugs may simply be loaded in 
targeted NPs or conjugated to reactive groups in NPs directly or by some 
environment-sensitive drug-binding linkers. These linkers will be 
broken in the reductive/acidic microenvironment of cytoplasm of tumor 
cells, which then leads to drug release and death of tumor cells 
stability. For instance, 5-fluorouracil (5-FU)-loaded poly(N­
vinylcaprolactam)-b-PEG-FA micelles with a lower critical so­
lution temperature of 33 °C were generated, which showed a 
slow and sustained release at 37 °C up to 30 h. Moreover, while 
FA-targeted micelles exerted remarkable toxicity against FR-
positive 4T1 cells, they had no significant toxicity on FR­
negative EA.hy 926 human endothelial cell line [24]. 
Interestingly, it has been demonstrated that polymeric micelles 
can also be used for photodynamic therapy (PDT). In this meth­
od, a tumor tissue is destroyed through light-induced chemical 
reaction. Consistently, Syu et al. generated a FA-conjugated 
meta-tetra (hydroxyphenyl)chlorin (m-THPC)-loaded micelles. 
They showed that FA-conjugated m-THPC-loaded micelles are 
engulfed and accumulated by FR-expressing KB cells both 
in vitro and in vivo. Moreover, the encapsulated m-THPC had 
no remarkable side effects on the body weight of mice [25]. 
Regarding these reports (Table 1), it seems that FA-targeted 
nanomicelles may be considered as potent devices in drug de­
livery into FR-positive tumors. However, little is known regard­
ing the efficiency of these NPs in in vivo human tumors, and 
this issue needs further investigations. 
Albumin nanoparticles 
The protein nanoparticles can bind to a large number of drugs 
in a relatively non-specific manner. Because of their surface 
charge, drugs can physically adsorb onto the protein surface or 
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Fig. 2 A schematic representation of some NPs used as drug delivery 
systems. a Micelles are self-assembled amphiphilic NPs that can 
encapsulate both lipophilic or lipophobic drugs. b Albumin can deliver 
lipophilic molecules to cancer cells. c Drug-loaded magnetic NPs can be 
magnetically conducted into cancer cells using an external magnet. d 
Mesoporous silica NPs can be used as multifunctional drug delivery 
can covalently bind to the matrix. Bovine serum albumin 
(BSA) and human serum albumin (HSA) have been widely 
used over the past 30 years to prepare micro- and NPs [26]. 
HSA is a negatively charged plasma protein (42–54 g/l) with a 
small size, which is produced in the liver and involved in 
different physiological processes such as long-chain fatty 
acids solubilization, nutrients delivery to cells, induction of 
colloidal osmotic pressure in the blood, controlling plasma 
system. e Gold NPs can be used as multifunctional imaging and 
therapeutic agents. f Dendrimers have ability to encapsulate or 
covalently conjugate drugs, targeting moieties, and imaging agents. g 
Chitosan NPs have wide variety of advantages to deliver several 
therapeutic molecules to cancer cells 
pH, and binding to bilirubin and drugs. As HSA is a source 
of amino acid for metabolism of cells, albumin can be used as 
a carrier for the drug delivery to tumor cells [27]. Tumor cells 
secrete an albumin-binding protein (also known as BM-40), 
which can help to the preferential uptake of albumin NPs by 
these cells [28]. Albumin NPs have several advantages such as 
biodegradability, less toxicity and antigenicity, high stability, 
controllable drug release, shelf life, and high loading potential 
Tumor Biol. (2015) 36:5727–5742 5731 
Table 1 Studies related to the role of FA-targeted micelles and albumin NPs in cancer therapy 
Nanoparticles Drug Findings Ref. 
Polymeric micelles 
FA-PTL-PLA-MPEG micelle 
FA-DOX-PLA-PEG- polymeric micelles 
FA-platinum-polymeric micelles 
FA-DOX-pH-sensitive polymeric micelles 
FA-DOX-PEG-poly(ε-caprolactone) micelles 
FA-poly(ε-caprolactone)-b-poly[triethylene
 
glycol methacrylate-co-N-methacryloyl
 
caproic acid] and poly(ε-caprolactone)-b­
poly[triethylene glycol methacrylate-co-N­
(2-(methacrylamido)ethyl] NPs
 
FA-PEG-poly(aspartate hydrazone adriamycin) 
FA-DOX-poly(N-isopropylacrylamide-co­
N,N-dimethylacrylamide-co-2-aminoethyl 
methacrylate)-b-poly(10-undecenoic acid) micelles 
FA-DOX-polyurethane micelles 
FA-5-FU-poly(N-vinylcaprolactam)-b-PEG 
micelles 
FA-meta-tetra(hydroxyphenyl)chlorin 
(m-THPC) micelles. 
Albumin nanoparticles 
FA-BSA 
FA-paclitaxel-BSA 
FA-albumin-bound formulation of
 
paclitaxel (Abraxane ABI-007)
 
FA-DOX-BSA-dextran 
FA-DOX-albumin nanospheres 
FA-5-FU-BSA-carboxymethyl­
β-cyclodextrin
 
FA-ergosta-4,6,8(14),22-tetraen-3­
one (ergone)-albumin nanospheres
 
FA-vinblastine sulfate-albumin NPs
 
FA-tamoxifen-albumin NPs 
FA-BSA nanospheres-DOX and
 
encapsulated magnetic iron oxide
 
FA-mitoxantrone-loaded albumin NPs 
– 
Doxorubicin 
Platinum 
Doxorubicin 
Doxorubicin 
Doxorubicin 
Aspartate hydrazone 
adriamycin 
Doxorubicin 
Doxorubicin 
5-FU 
Meta-tetra(hydroxyphenyl) 
chlorin 
– 
Paclitaxel 
Paclitaxel 
Doxorubicin 
Doxorubicin 
5-FU 
Ergosta-4,6,8(14),22­
tetraen-3-one (ergone) 
Vinblastine sulfate 
Tamoxifen 
Doxorubicin 
Mitoxantrone 
Folate conjugation increases the stability of NPs. [16] 
DOX-loaded NPs could markedly kill FR-expressing [17] 
SKOV3 human ovarian cancer cells, in vitro. 
Platinum loaded NPs exert potent anti-tumoral effect [18] 
both in vitro and in vivo. 
FA-conjugated micelles could effectively inhibit tumor [14] 
growth in 4T1 tumor-bearing mice. 
DOX-loaded micelles exerted potent anti-tumor function [19] 
in both in vitro and in vivo. 
DOX-loaded ph-sensitive NPs exerted high toxicity [20] 
against FR-expressing HeLa cells, in vitro. 
Aspartate hydrazone adriamycin LOADED NPs stopped [21] 
the growth of human pharyngeal cancer cells 
(KB cell) in vitro. 
DOX-loaded micelles effectively inhibited the tumor [22] 
burden both in vitro and in vivo. 
Redox- and pH-sensitive nanomicelles inhibited the [23] 
growth of FR-positive HeLa cells in vitro. 
Thermosensitive 5-FU-loaded micelles exerted [24] 
remarkable toxicity against FR-positive 4T1 cells. 
Polymeric micelles can be useful for photodynamic [25] 
therapy both in vitro and in vivo 
BSA NPs could effectively uptake SKOV3 cells in vitro. [29] 
Paclitaxel-loaded BSA NPs effectively deliver anti- [30] 
cancer drug into a human prostate cancer PC3 cell 
line. 
Albumin-bound formulation of paclitaxel (Abraxane [32] 
ABI-007) has been evaluated in phase III trial for 
treatment of breast cancer. 
DOX-loaded BSA-dextran NPs exert remarkable [35] 
anti-tumor activity in vivo. 
DOX-loaded albumin nanospheres kill the FR- [36] 
expressing tumor cells in vitro. 
5-FU-loaded NPs exhibited high inhibition and promote [37] 
apoptosis in FR-expressing tumor cells. 
Ergone-loaded albumin nanospheres could selectively [38] 
kill tumor cells, in vitro and in vivo. 
Albumin NPs could selectively deliver vinblastine sulfate [39] 
(VBLS) anti-cancer drug to tumor cells. 
Tamoxifen-loaded albumin NPs inhibit tumor growth [40] 
in vitro. 
DOX-loaded BSA NPs which encapsulated magnetic [41] 
iron oxide in combination with hyperthermia improve 
the therapeutic effect of anti-tumor drugs in both 
in vitro and in vivo. 
Mitoxantrone-loaded albumin NPs could effectively [42] 
control the growth of SKOV3 tumor cells both 
in vitro and in vivo. 
for hydrophilic drugs, which make them a potent candidate in these NPs [4]. Consistently, there is evidence, which implies 
drug delivery to tumor cells [29]. Conjugation of albumin NPs the effectiveness of FA-conjugated albumin NPs in drug de­
with folate can provide site-specific targeting properties for livery to cancer cells [29, 30] (Table  1). Zhang et al. showed 
5732 Tumor Biol. (2015) 36:5727–5742 
that FA-conjugated BSA NPs could effectively uptake 
SKOV3 cells in vitro [29]. It has also been reported that FA­
conjugated paclitaxel-loaded BSA NPs selectively deliver 
anti-cancer drug into a human prostate cancer PC3 cells 
[30].  The first  HSA-based NP formulation, ABI 007 
(Abraxane®),  was approved by the Food and Drug 
Administration (FDA) in 2005 [31]. ABI-007 is a novel, al­
bumin-bound, 130-nm particle formulation of paclitaxel, free 
from any kind of solvent (polyethoxylated castor oil— 
Cremophor-free). It is used as a colloidal suspension derived 
from the lyophilized formulation of paclitaxel and HSA dilut­
ed in saline solution. In detail, HSA stabilizes the drug particle 
at an average size of 130 nm which prevents any risk of cap­
illary obstruction and does not necessitate any particular infu­
sion systems or steroid/antihistamine premedication before 
the infusion [32]. There are some trials related to the use of 
albumin-based NPs for treatment and diagnosis of breast and 
brain tumors, respectively [33, 34]. Hao et al. have recently 
prepared FA-conjugated DOX-loaded BSA-dextran NPs for 
cancer drug delivery. It should be noted that the dextran shell 
makes the NPs more dispersible in solution. They showed that 
these NPs allow to the administration of the higher doses of 
DOX and exert remarkable anti-tumor activity in murine as-
cites hepatoma H22 tumor-bearing mice [35]. The similar re­
sults have been observed following the use of DOX-loaded 
FA-conjugated albumin nanospheres in FR-positive HeLa 
cells and FR-negative aortic smooth muscle cells (AoSMC) 
[36]. FA-targeted 5-FU-loaded BSA-carboxymethyl-β­
cyclodextrin NPs have also exhibited high inhibition and pro­
mote apoptosis in FR-expressing HeLa cells as compared to 
free drug and non-targeted NPs [37]. It has recently been 
demonstrated that FA-conjugated ergosta-4,6,8(14),22­
tetraen-3-one (ergone)-loaded albumin nanospheres could se­
lectively kill KB tumor cells, in vitro. In vivo experiments 
using murine animal models more substantiated the efficacy 
of these NPs in tumor targeting [38]. FA-conjugated albumin 
NPs could selectively deliver vinblastine sulfate (VBLS) anti­
cancer drug to tumor cells [39]. The intravenous administra­
tion of tamoxifen-loaded FA-conjugated albumin NPs to nude 
mice carrying xenograft MCF-7 tumors was associated with 
potent anti-tumor effects and the lowest levels of drug accu­
mulated in non-targeted tissues [40]. On the other hand, Yang 
and colleagues have shown that administration of FA­
conjugated BSA nanospheres comprising DOX and encapsu­
lated magnetic iron oxide in combination with hyperthermia 
significantly decreases the adverse effects and improves the 
therapeutic effect of anti-tumor drugs in both in vitro and 
in vivo [41]. Similarly, mitoxantrone-loaded FA-conjugated 
albumin NPs could effectively control the growth of SKOV3 
tumor cells both in vitro and in vivo [42]. 
Regarding high compatibility, availability, and drug load­
ing, it seems that FA-conjugated albumin NPs may have a 
potent therapeutic potential as the vector of anti-cancer drugs. 
Magnetic nanoparticles 
Superparamagnetic NPs made from ferrite oxide-magnetite 
(Fe3O4) are the most magnetic NPs used in biological appli­
cations [43]. Magnetic NPs can be manipulated through mag­
netic field [44]. Although the application of magnetic NPs 
dates back to the 1970s [45], high attention has recently been 
focused on them, which is in part related to their unique fea­
tures such as high surface to volume ratio, quantum size effect, 
and magnetic character [45, 46]. Although the size and surface 
functionality of magnetic NPs remarkably affect their efficien­
cy, superparamagnetic iron oxide NPs (SPIOs) diameters 
mainly affect their in vivo biodistribution. Moreover, ultra­
small SPIOs with diameters of 10 to 40 nm show prolonged 
blood circulation and cross capillary walls and are usually 
engulfed by macrophages [47]. Magnetic NPs can be applied 
in several ways, including magnetic drug targeting [46], mag­
netic fluid hyperthermia [48], and contrast agents for magnetic 
resonance imaging (MRI) [49, 50, 46, 51, 52]. Among the 
magnetic NPs, Fe3O4 NPs are only approved by the US 
FDA for clinical use [53, 45]; however, it has a short half-life, 
no specific tumor-targeting effect, and readily phagocytosed 
by mononuclear phagocyte system and removed by macro­
phages [41]. Magnetic NPs are usually composed of inner 
magnetic core (Fe3O4 or Fe2O3) and an outer polymeric shell. 
The polymeric shell provides biocompatibility, prevents ag­
glomeration, and acts as a drug reservoir. Several polymers 
such as starch, dextran [54, 55], PEG [51, 56], fatty acids, 
polyvinyl alcohol [57], polyacrylic acid, poly lactides, gelatin, 
silica [58, 59, 56], oleic acid [60, 61], PLGA or poly(D,L-lactic­
co-glycolic acid) [62], polyethylene imine (PEI) [63], poly 
methyl methacrylate (PMMA), and polyacrylic acid (PAA) 
[59, 64], albumin [50, 41], and chitosan [64] have been used  
as coatingmaterials for different purposes. Conjugation of outer 
shell with different targeting molecules can promote site-
specific function of magnetic NPs. It has been shown that con­
jugation of SPIOs with amino-terminal fragment [65] and RGD  
peptides [66] could specifically target tumor cells. Moreover, 
the amino-functionalized Fe3O4, MnFe2O4, and Mn3O4 mag­
netic NPs conjugated with rhodamine B (a fluorescent dye) and 
FA could specifically target cancer cells overexpressing FRs 
[67]. Similarly, it is reported that FA-conjugated Fe3O4 NPs 
modified by dopamine-PEG-NH2 and fluorescein isothiocya­
nate (FITC) could effectively recognize the FR-positiveMCF-7 
cells, but not the FR-negative A549 cells [49]. Interestingly, it is 
suggested that microbial exopolysaccharides can be applied as 
biocompatible shell polymers for magnetic NPs. Sivakumar 
and colleagues have recently demonstrated that 5-FU-loaded 
FA-conjugated magnetic  NPs coated with  bacterial  
exopolysaccharides mauran and gellan gum in combination 
with hyperthermia effectively killed cancer cells. They have 
recommended that mauran and gellan gum coated magnetic 
NPs have high biocompatibility, low cytotoxicity, high 
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therapeutic potential, and superparamagnetic behavior that can 
be applied as worthy tools for bacterial exopolysaccharide­
based targeted drug delivery, cancer cell imaging, and magnetic 
hyperthermia [68]. Most recently, Ma and coworkers generated 
FA-albumin conjugated SPIO NPs, which had a strong MRI 
efficacy in MCF-7 and SPC-A-1 cells due to the recognition of 
FR [50]. DOX-loaded FA-targeted magnetic Fe3O4 NPs could 
also significantly kill C30 and CP70 human ovarian cancer cells 
in vitro, whichwas associatedwith downregulation of bcl-2 and 
survivin and upregulation of caspase-3 [69]. Similar results 
were observed when FA-conjugated SPIO-based magnetic 
NPs were incubated with human leukemic CCRF-CEM cells 
[70]. Similarly, idarubicin-loaded PEG-covered magnetic NPs 
showed higher toxicity in MCF-7 cells compared to free 
idarubicin [71]. Interestingly, it has recently been demonstrated 
that the peroxidase-like activity of Fe3O4@ carbon NPs can 
modulate oxidative stress induced by ascorbic acid for the se­
lective killing of PC-3 prostate cancer cells through production 
of high levels of endogenous ROS [72]. In addition, Li et al. 
have demonstrated that amine-modified group in the surface of 
core-shell Fe2O3@ carbon NPs can be functionalized with PEG 
and FA to enhance their solubility in aqueous solution and 
target cancer cells [73]. 
It is suggested that incorporation of Fe3O4 into FA­
conjugated BSA NPs inhibits their clearing by mononuclear 
phagocyte system [41, 50]. Active targeting through FA­
conjugated magnetic NPs is mainly dependent to density of 
FA on magnetic NPs and FR on the tumor cells as assessed in 
4T1 bearing BALB/c mice [74]. 
The higher sensitivity of tumor cells to high temperatures 
compared to normal cells, which is in part due to hypoxic 
condition of tumor area, led to a combinatorial application of 
magnetic NPs and hyperthermia to destroy tumor cells [75, 76, 
68]. Addition of some chemotherapeutic drugs in the above-
mentioned combination therapy could increase the efficacy of 
tumor cell killing [77–79, 68]. There are studies which indicate 
the administration of chemotherapeutic drugs (daunorubicin 
and 5-bromotetrandrine)-loaded Fe3O4 magnetic NPs sup­
presses tumor proliferation and enhances apoptosis in a dose­
and time-dependent manner, both in vitro and in vivo [80, 81]. 
Several other biocompatible magnetic NPs such as dextran­
stabilized magnetic fluid, aminosilane-modified NPs, cationic 
magnetoliposomes, and affinity magnetoliposomes have also 
been used for hyperthermia treatment [82, 83]. Magnetic hy­
perthermia makes it possible for the heating to be limited to 
the tumor site [84, 85, 68]. The use of external magnetic field 
in combination with magnetic NPs can conduct magnetic 
nanocarrier to the desired tumor site, fix them, and release 
the drug locally [86–88]. It is demonstrated that combination 
of hyperthermia and chemotherapy not only increases the drug 
concentration in tumor cells but also decreases the drug-
related adverse effects to normal tissue and inhibits the drug 
resistance [89, 79]. The unique feature of tumor cells to absorb 
magnetic NPs (8–400-fold more than normal cells) makes 
them highly susceptible to magnetic fluid hyperthermia [41]. 
Electromagnetic fields (EMFs) are other noninvasive use­
ful devices, which can be applied in combination with mag­
netic NPs. It is demonstrated that frequencies lesser than 
300 Hz (known as extremely low frequency or ELF) do not 
exert damage to deoxyribonucleic acid (DNA) [62]. Using this 
approach, Wen and colleagues have shown that FA­
conjugated magnetic NPs in combination with ELF-EMF 
could selectively induce apoptosis in BEL-7402 liver cancer 
cells [53]. ELF-EMF enhances anti-tumor function of mag­
netic NPs in part through affecting cell ion metabolism via the 
reduction of cation-exchange across the cell membrane [90]. 
The possibility of combining magnetic NPs with other cancer 
therapeutic methods makes them as worthy candidates for 
cancer therapy (Table 2). 
Mesoporous silica nanoparticles (MSN) 
Silica has more biocompatibility and lower cytotoxicity than 
other metal oxides such as titania and iron oxide [91]. The 
high levels of silanol groups in silica enhance its affinity to 
phospholipids, so it can be easily taken up by the cells. The 
high surface area (>900 m2/g) and pore volume (>0.9 cm3/g) 
make it possible to load high doses of different drugs [92]. 
Due to the presence of strong Si–O bond [93] in silica NPs, 
they have high resistance against mechanical stress, heat, pH, 
and hydrolysis-induced degradations compared to liposomes 
and dendrimers [92, 94, 95]. The sol-gel process is a common 
methodology to create mesoporous silica NPs [96]. The rate of 
drug release from mesoporous silica NPs depends on the size 
of pores, which can be controlled by the processing parame­
ters, such as temperature, pH, solvents, raw materials, cata­
lysts, precursor, and additives in different concentrations [97, 
91]. MCM-41 and SBA-15 are two common mesoporous sil­
ica materials, which have different pore sizes, including 2– 
5 nm  and 5–10 nm, respectively. The smaller pore size helps 
to slow drug release and provides higher stability in mesopo­
rous silica NPs [98, 97, 92]. In addition, the surface 
functionalization of silica NPs with different molecules allows 
developing silica NPs with various surface properties [96, 99]. 
Regarding the high expression of FR on tumor cells, several 
studies have tried to conjugate mesoporous silica NPs with FA 
to achieve effective drug delivery to tumor cells [100, 93, 101, 
102] (Table 3). Consistently, it is reported that FA-targeted 
camptothecin or paclitaxel-loaded multifunctional mesopo­
rous silica NPs could be effectively used for cancer imaging, 
targeting, and drug delivery in FR-expressing human pancre­
atic cancer cells PANC-1 and BxPC-3 [93]. Fan and col­
leagues have developed the pH-sensitive FA-conjugated 
DOX-loaded mesoporous silica NPs, which could selectively 
kill FR-expressing HeLa cells, but not FR-negative A549 and 
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Table 2 Studies related to the role of FA-targeted magnetic NPs in cancer therapy 
Nanoparticles Drug Findings Ref. 
Magnetic nanoparticles 
FA-Fe3O4, FA-MnFe2O4, and FA-Mn3O4 
magnetic NPs conjugated with 
rhodamine B 
FA-Fe3O4-dopamine-PEG-NH2-FITC 
FA-5-FU magnetic NPs coated with
 
bacterial exopolysaccharides
 
FA-albumin conjugated SPION NPs 
FA-DOX Fe3O4 magnetic NPs 
FA-SPION-based magnetic NPs 
FA-idarubicin-PEG-covered magnetic 
NPs 
FA-PEG-Fe2O3@ carbon NPs 
FA-Fe3O4 into conjugated BSA
 
NPs
 
FA-magnetic NPs
 
FA-magnetic NPs 
FA-dextran/retinoic-magnetic iron oxide 
NPs and FA-polyethylenimine 
magnetic NPs 
FA-curcumin and 5-FU-magnetic NPs­
poly(D,L-lactic-co-glycolic acid) 
FA-magnetic NPs 
– 
– 
5-FU 
– 
Doxorubicin 
– 
Idarubicin 
– 
– 
– 
cis-Diamminedichloroplatinum 
cisplatin and 5-FU 
Doxorubicin 
Curcumin and 5-FU 
– 
FA-conjugated magnetic NPs cells selectively target 
FR-expressing cancer cells. 
FA-conjugated magnetic NPs cells selectively target 
FR-expressing cancer cells. 
5-FU-loaded magnetic NPs coated with bacterial 
exopolysaccharides in combination with 
hyperthermia effectively killed cancer cells. 
Albumin SPION NPs had a strong MR imaging efficacy. 
DOX-loaded magnetic NPs kill FR-expressing human 
ovarian cancer cells in vitro through downregulation 
of bcl-2 and upregulation of caspase-3. 
SPION-based magnetic NPs inhibit the growth of FR­
expressing human leukemic CCRF-CEM cell Line. 
Idarubicin-loaded PEG-covered magnetic NPs kill FR­
expressing MCF-7 in vitro. 
Fe2O3@ carbon NPs can be functionalized with PEG 
and folic acid to enhance their solubility in aqueous 
solution and target cancer cells. 
Fe3O4-BSA-FA NPs resist against clearing by 
reticuloendothelial cells. 
Active targeting is dependent to density of FA on magnetic 
NPs and FR on the tumor cells. 
The combination of magnetic induced hyperthermia, 
chemotherapy and FA-targeted radionuclide of radiation 
exposure significantly inhibit the growth of tumor. 
The use of external magnetic field in combination with 
magnetic NPs can conduct magnetic nanocarrier to the 
desired tumor site, fix them and release the drug locally. 
Combination of hyperthermia and chemotherapy 
increases the efficiency of anti-tumor therapy. 
Magnetic NPs in combination with extremely low­
frequency- electromagnetic fields effectively 
kill cancer cells. 
[67] 
[49] 
[68] 
[50] 
[69] 
[70] 
[71] 
[73] 
[41, 50] 
[74] 
[68, 85] 
[86, 87] 
[79] 
[53] 
L929 cells [100]. Mahapatra and coworkers have also pro­
duced FA-conjugated hybrid NPs composed of multifunction­
al mesoporous hollow silica NPs, which encapsulated 
superparamagnetic CoFe2O4 NPs for targeted co-delivery of 
cisplatin-pemetrexed and MR imaging. Their generated drug­
loaded nanospheres exhibited enhanced cytotoxicity against 
FR-positive HeLa cells, but not HaCat and 3T3 cells [101]. 
Sahoo and colleagues have similarly prepared mesoporous 
silica-coated super  paramagnetic  manganese ferrite  
(MnFe2O4) NPs conjugatedwith FA for targeted drug delivery 
and MR imaging applications. The DOX-loaded NPs could 
selectively kill HeLa cancer cells both in vitro and in vivo 
[58].  Other investigators have designed mechanized 
nanocontainers via conjugating interlocked molecules, 
rotaxanes, onto the orifices of mesoporous silica NPs through 
disulfide bond. They showed that DOX-loaded mechanized 
nanocarriers could selectively kill tumor cells in vitro and 
in vivo [102]. MA and coworkers have recently developed 
FA-conjugated  hollow mesoporous  silica NPs  for  
simultaneously delivering both DOX and small interfering 
RNA (siRNA) against the Bcl-2 protein into tumor cells. 
Their results showed that FA-conjugated NPs could potently 
kill high-expressing FR cells (HeLa) compared to low­
expressing FR cells (MCF-7) [99]. Moreover, Teng et al. de­
veloped folate-targeted phospholipid-functionalized mesopo­
rous silica NPs for selective photodynamic therapy of tumor 
cells in vitro and in vivo. They showed that their developed 
nano-photodynamic therapy systems could effectively enter 
into the FR-overexpressed HeLa cells. In addition, this thera­
peutic method could significantly decrease tumor growth in 
nude mice inoculated with B16F10 cells [103]. 
Gold nanoparticles 
Gold NPs have been used for far years in techniques such as 
transmission electron microscopy (TEM) and atomic force 
microscopy (AFM) [104]. There are conflicting reports 
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Table 3 Studies related to the role of FA-targeted mesoporous silica and gold NPs in cancer therapy 
Nanoparticles Drug Findings Ref. 
Mesoporous silica NPs 
FA-camptothecin or paclitaxel 
multifunctional mesoporous silica 
NPs 
FA-DOX-mesoporous silica NPs 
FA-cisplatin-pemetrexed-mesoporous 
hollow silica-CoFe2O4 NPs 
FA-DOX-mesoporous silica-coated 
super paramagnetic manganese 
ferrite (MnFe2O4) NPs  
FA-DOX-mesoporous silica NPs 
FA-DOX and Bcl-2 siRNA­
mesoporous silica NPs
 
FA-phospholipid-functionalized
 
mesoporous silica NPs
 
Gold nanoparticles 
FA-berberine hydrochloride-gold NPs 
FA-BSA-gold NPs 
FA-6-mercaptopurine (6MP)-gold NPs 6-mercaptopurine (6MP) 
FA-5-FU-pullulan stabilized gold NPs 5-FU 
FA-PEG-dendrimer-entrapped gold γ-tocopheryl succinate (γ-
NPs TOS) 
FA-gold nanorods – 
FA-gold NPs –
 
FA-gold NPs –
 
Multifunctional mesoporous silica NPs are useful for cancer [93] 
imaging, targeting, and drug delivery in FR-expressing human 
cancer cells. 
The pH-sensitive DOX-loaded mesoporous silica NPs selectively [100] 
kill FR-expressing cancer cells. 
Multifunctional mesoporous silica NPs which encapsulated [101] 
superparamagnetic CoFe2O4 NPs are effective for targeted 
drug delivery and tumor imaging. 
Mesoporous silica-coated super paramagnetic manganese ferrite [58] 
(MnFe2O4) NPs are useful for targeted drug delivery and tumor 
imaging 
DOX-loaded mechanized nanocontainers could selectively kill [102] 
tumor cells in vitro and in vivo 
DOX and Bcl-2-siRNA loaded mesoporous silica NPs potently [99] 
kill high-FR-expressing cancer cells. 
FA-targeted phospholipid-functionalized mesoporous silica NPs [103] 
are effective for selective photodynamic therapy of tumor cells 
in vitro and in vivo. 
Berberine hydrochloride loaded gold NPs selectively kill FR- [118] 
expressing cancer cells 
BSA-conjugated gold NPs selectively target FR-expressing [110] 
cancer cells 
6-mercaptopurine (6MP)-loaded gold NPs potently kill [119] 
FR-expressing cancer cells both in vitro and in vivo. 
5-FU-loaded pullulan stabilized gold NPs significantly decrease [120] 
growth of tumor cells both in vitro and in vivo. 
The theranostic potential of multifunctional dendrimer-entrapped [121] 
gold NPs was confirmed both in vitro and in vivo. 
The combination of folate-conjugated gold nanorods with the [126] 
photo-thermal therapy is useful for the selective targeting and 
destruction of cancer cells. 
FA-conjugated gold nanoclusters can be used as fluorescence [127] 
enzyme mimetic nanoprobes for tumor imaging. 
Electrochemical cytosensor containing FA-conjugated gold NPs [128] 
are able to detect cancer cells.  
Camptothecin and paclitaxel 
Doxorubicin 
Cisplatin and pemetrexed 
Doxorubicin 
Doxorubicin 
Doxorubicin and siRNA 
against the Bcl-2 
– 
Berberine hydrochloride 
– 
regarding the toxicity of gold NPs both in vitro and in vivo 
[105]. Gold NPs have successfully been used for several bio­
medical approaches such as photo-thermal therapy [106, 107], 
cancer diagnosis [108], tumor imaging [109, 110], and drug 
delivery [111, 108]. The plasmon resonance features of gold 
NPs enable their detection in biological systems [112]. Gold 
NPs can bind to amine and thiol groups, which make it pos­
sible to modify their surface and their usage in medical appli­
cations [113]. The high surface to volume ratio provides an 
optimum condition in which hundreds of molecules such as 
drugs, targeting agents, and anti-fouling polymers can be coat­
ed on the surface of gold NPs. As gold NPs can pass across 
leaky blood vessels, they may be considered as potent 
nanocarriers for drug delivery into solid tumors with high 
angiogenesis potential [114]. It is suggested that gold NPs 
enter into the cells through non-specific receptor-mediated 
endocytosis  mechanism [115].  Since the  systemic  
administration of gold NPs without targeting moieties can be 
associated with toxic side effects against normal tissues, its 
surface modification with targeting molecules such as FA 
can increase their efficiency and decrease their adverse effects 
[116, 117] (Table  3). Pandey and coworkers have developed 
FA-conjugated berberine hydrochloride-loaded gold NPs, 
which can selectively kill FR-expressing HeLa cells [118]. 
Another group used BSA-conjugated gold NPs, which was 
surface modified by FA. They showed that while the BSA­
gold NPs had no effects on the MGC803 gastric cancer cells, 
FA-modified NPs could selectively target them [110]. 
Similarly, FA-conjugated 6-mercaptopurine (6MP)-loaded 
gold NPs could potently kill FR-expressing HeLa and KB 
cells both in vitro and in vivo [119]. It has also been shown 
that FA-targeted 5-FU-loaded pullulan stabilized gold NPs 
could significantly decrease the amount of 50 % of growth 
of inhibition (IC50) when incubated with HepG2 cancer cells. 
5736 Tumor Biol. (2015) 36:5727–5742 
Moreover, these NPs had higher concentrations in liver of 
zebrafish embryo, as an in vivo model, compared to non-
targeted gold NPs [120]. Zhu and colleagues recently devel­
oped multifunctional dendrimer-entrapped gold NPs, which 
were conjugated with PEGylated FA and linked with γ­
tocopheryl succinate (γ-TOS) as a platform for targeted can­
cer imaging and therapy. The theranostic potential of their 
targeted NPs was approved both in vitro and in vivo using 
U87MG and L929 cancer cells [121]. 
The thermal characteristics of gold NPs, which let them to 
convert the absorbed laser light energy into localized heat, 
make them as worthy tools for application in combination 
with photo-thermal therapy for selective destruction of cancer 
cells [122–125]. Mehdizadeh and colleagues have used the 
combination of FA-conjugated gold nanorods with the 
photothermal therapy for the selective targeting and destruc­
tion of mouth epidermal carcinoma KB cells. While none of 
the treatments alone had effects on the cancer cells, their com­
bination could significantly kill them [126]. FA-conjugated 
gold nanoclusters have also been used as fluorescence enzyme 
mimetic nanoprobes for tumor diagnosis and distinguishing 
tumor cells from normal cells [127]. Moreover, Xu et al. have 
designed an electrochemical cytosensor containing FA-
conjugated gold NPs and signal indicator (ferrocene), which 
was able to effectively detect specific cancer cell and signal 
magnification for improving detection sensitivity [128]. 
Regarding the above-discussed studies, it seems that FA­
conjugated NPs in combination with photo-thermal therapy 
may be effective for specific cancer therapy. 
Dendrimers 
Dendrimers are branched polymeric molecules with several 
arms extending from a center, leading to almost perfect 
three-dimensional geometric pattern. Two common strategies, 
including divergent and convergent methods, have usually 
been used for synthesis of dendrimers, which differ in direc­
tion of production, either core to out or inwardly out to core, 
respectively [129]. While the branches of dendrimers increase 
exponentially with their generation (G), their diameter in­
creases up to about 1 nm with the generation. 
Polyamidoamine (PAMAM) is an important subtype of 
dendrimers, which has a high efficiency to carry small thera­
peutic drugs. The cationic form of PAMAM is a worthy tool 
for delivery of therapeutic oligonucleotides. The tertiary 
amines and amide linkages of PAMAMs facilitate the attach­
ment of numerous targeting and guest molecules. The hydro­
phobic core of PAMAMs enables them for the encapsulation 
of different therapeutic molecules [130]. Modification of ter­
minal groups of dendrimers can create both a hydrophilic or 
lipophilic molecules for the desired biological and drug deliv­
ery application [131]. Since there are several reactive groups 
on dendrimers, their surface modification can be easily per­
formed for specific targeting. It is reported that conjugation of 
dendrimers with biological targeting moieties such as FA can 
significantly increase their specific function on tumor cells 
in vitro (using KB cells) [132] (Table  4). The selective 
in vitro cytotoxicity of FA-conjugated methotrexate-loaded 
dendrimers against tumor cells confirms former report [133]. 
Kesharwani et al. have recently analyzed the anti-tumor po­
tential of different generations of FA-targeted Melphalan­
loaded poly(propyleneimine) (PPI) dendrimers both in vitro 
(MCF-7 cells) and in vivo. They have suggested that the 
fourth generation PPI dendrimer is a better carrier for targeted 
cancer therapy compared to the third and fifth generations 
[134]. Other investigators have investigated the effect of sur­
face capping via different groups (including -OH, -COOH, 
and -NH2) on tumor-targeting efficiency of FA-conjugated 
PPI dendrimers. Their results showed that COOH-capped 
dendrimers have the highest tumor-targeting potential (as 
assessed in HeLa and SiHa cells) compared to other formula­
tions [135]. The high anti-tumor gene delivery potential of 
FA-conjugated fifth generation (G5) PAMAM dendrimers in­
to KB cancer cells has been demonstrated by other investiga­
tors [136]. Consistently, Arima and colleagues have reported 
that FA-PEG-appended polyamidoamine dendrimer (G3) con­
jugate with γ-cyclodextrin exhibits high efficiency for gene 
delivery into FR-overexpressing (KB), but not FR-negative 
(A549), cells, both in vitro and in vivo [137]. The high gene 
transfection potential of dendrimers was also demonstrated 
using a pH-sensitive FA-PEG-chitosan-PAMAM-plasmid 
DNA (containing a high mobility group box 1, HMGB1) 
complexes both in vitro (in KB cells) and in vivo (S180 xe­
nograft nude mice) [138]. The rapid elimination of such a 
small NPs is one of their important limitations. Thus, 
Sunoqrot and coworkers have developed a multi-scale hybrid 
NP platform that loads PAMAM dendrimers into PEG-PLA 
NPs. Their generated hybrid NPs had higher circulation time 
compared to dendrimer. Moreover, these hybrid NPs could 
selectively reach to FR-expressing KB tumor cells, in vivo 
[139]. 
It seems that dendrimers can be considered as potent ther­
apeutic gene carriers in biomedical applications. Moreover, 
hybridization of dendrimers with some polymers could pro­
mote their efficiency for in vivo approaches. 
Chitosan nanoparticles 
Chitosan is a linear polysaccharide derived from alkaline N­
deacetylation of chitin and composed of randomly distributed 
N-acetyl-glucosamine and glucosamine residues with β-1,4­
linkage [140]. As chitosan is soluble in acid condition, it can 
be applied for drug delivery in an acidic environment [141, 8]. 
In addition to pH, degree of deacetylation, molecular weight, 
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Table 4 Studies related to the role of FA-targeted dendrimer and chitosan NPs in cancer therapy 
Nanoparticles Drug Findings Ref. 
Dendrimer NPs 
FA-dendrimer 
FA-MTX-dendrimers 
FA-Melphalan-poly(propyleneimine) 
(PPI) dendrimers 
FA-(PPI) dendrimers. 
FA-DNA-fifth generation (G5) PAMAM 
dendrimers 
FA-DNA-PEG- polyamidoamine 
dendrimer (G3)-γ-cyclodextrin 
FA-PEG-chitosan-PAMAM-plasmid 
DNA (containing a high mobility 
group box 1, HMGB1) 
PAMAM-PEG-b-poly(D,L-lactide) 
(PEG-PLA) NPs 
Chitosan 
FA-DOX-chitosan NPs 
FA-copper ion-acetylacetone-chitosan NPs – 
FA significantly increases the specific function of NPs in tumor [132] 
cells in vitro 
MTX loaded dendrimers selectively kill tumor cells [133] 
The fourth generation PPI dendrimer is the best carrier for [134] 
targeted cancer therapy. 
COOH capped dendrimers have the highest tumor-targeting [135] 
potential 
The fifth generation (G5) PAMAM dendrimers have high [136] 
potential for gene delivery into cancer cells 
FA-PEG-appended polyamidoamine dendrimer (G3) conjugate [137] 
with γ-cyclodextrin exhibit high efficiency for gene delivery 
into FR-overexpressing cancer cells, both in vitro and in vivo. 
The high gene transfection potential of dendrimers in vitro [138] 
and in vivo. 
Hybrid NPs selectively target FR-expressing tumor cells in vivo [139] 
DOX-loaded chitosan NPs kill FR-expressing cancer cells, [144] 
in vitro. 
FA-tagged copper ion and acetylacetone encapsulated chitosan [145] 
NPs exhibit anti-tumor effects on the several 
FR-overexpressing cancer cells, in vitro. 
Gemcitabine loaded chitosan NPs exert potent anti-tumor [146] 
function on cancer cells both in vitro and in vivo. 
DNA loaded NPs exhibit the higher cellular uptake in [147] 
FR-expressing cancer cells. 
DOX-loaded NPs inhibit the growth of cancer cells both in vitro [148] 
and in vivo. 
Amino acid-modified chitosan NPs increased gene transfer into [149] 
FR-positive cancer cells, both in 3D spheroids and in 
vivo-mimicking 2D co-cultures 
DOX-loaded NPs exerted high toxicity against FR-positive [151] 
cancer cells, in vitro. 
HIF-1γ siRNA encapsulated NPs inhibited the tumor growth [152] 
in vivo. 
– 
MTX 
Melphalan 
– 
DNA 
DNA 
Plasmid DNA (containing a 
high mobility group box 1, 
HMGB1) 
– 
Doxorubicin 
FA-gemcitabine-PEG-chitosan NPs Gemcitabine 
FA-DNA-N-trimethyl chitosan NPs DNA 
FA-DOX-chitosan-dextran NPs Doxorubicin 
FA-PEG-p53 DNA-amino acid-modified p53 DNA 
chitosan NPs 
FA-DOX-chitosan-deoxycholic Doxorubicin 
acid–MPEG NPs 
FA-HIF-1γ siRNA -PEG-chitosan HIF-1γ siRNA 
oligosaccharide lactate NPs 
and ionic strength of the solution can potently affect the chi­
tosan solubility [142]. Chitosan exhibited several features, in­
cluding high biocompatibility and low cytotoxicity, which 
made it as a potent nanocarrier for targeted cancer therapy. 
However, due to the lack of cell-targeting ability and low 
transfection efficiency, it shows low therapeutic potential in 
common form. Thus, different derivatives of chitosan such as 
trimethyl chitosan (TMC), 6-amino-6-deoxy-chitosan 
(6ACT) (both are hydrophilic derivatives), N-alkylated chito-
san (ACS), and hydrophobically modified glycol chitosan 
(HGC) (both are hydrophobic derivatives) have been devel­
oped in order to improve the therapeutic potential of chitosan 
[143]. Moreover, several targeting molecules such as FA have 
also been conjugated with chitosan NPs in order to facilitating 
their selective function (Table 4). It is reported that FA­
conjugated DOX-loaded chitosan NPs could potently kill 
FR-expressing SMMC-7221 cells, in vitro [144]. FA-tagged 
copper ion and acetylacetone-encapsulated chitosan NPs were 
also  exerted  anti-tumor  effects  on the  several  FR­
overexpressing cancer cells, in vitro [145]. The similar results 
were observed using FA-conjugated gemcitabine-loaded 
PEG-chitosan NPs in COLO357 pancreatic cancer cells both 
in vitro and in vivo [146]. Zheng and colleagues have shown 
that FA-conjugated DNA-loaded TMC NPs exhibit the 
higher  cellular  uptake in  FR-expressing (KB and 
SKOV3) cells compared to non-targeted NPs. The cellu­
lar uptake of FA-conjugated NPs was significantly decreased 
in FR-negative (A549 and NIH/3T3) cells. Moreover, they 
suggested that FR-mediated uptake of NPs could be done 
through both FR-dependent and FR-independent endocytosis 
mechanisms [147]. The FA-targeted DOX-loaded chitosan­
dextran NPs could also inhibit the growth of cancer (KB) cells 
both in vitro and in vivo  [148]. Gaspar et al. reported 
that the use of FA-PEG-conjugated p53 DNA-loaded 
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amino acid-modified chitosan NPs significantly increased 
gene transfer into FR-positive cancer cells, both in 3D spher­
oids and in vivo-mimicking 2D co-cultures, which led to the 
decreased tumor-spheroids volume [149]. Interestingly, it is 
suggested that methotrexate, as a FA analogue, can effectively 
target cancer cells through binding to FR [150]. Shi and co­
workers have recently developed FA-conjugated DOX-loaded 
chitosan-deoxycholic acid–MPEG NPs, which exerted high 
toxicity against FR-positive HeLa but not FR-negative fibro­
blast 3T3 cells, in vitro [151]. It should be noted that 
deoxycholic acid contains the hydrophilic moieties and the 
hydrophobic nucleus, which allows forming micelles in water 
because of its amphiphilicity. Thus, deoxycholic acid can help 
in the self-association of chitosan and physical incorporation 
of hydrophobic drugs. In order to escape from the mononu­
clear phagocyte system, PEG molecules can be added to this 
complex. The systemic administration of FA-targeted HIF-1γ 
siRNA encapsulated-PEG-chitosan oligosaccharide lactate 
(FA-PEG-COL) NPs into BALB/c mice bearing OVK18 #2 
tumor xenograft was associated with remarkable tumor hin­
drance compared to non-targeted NPs that implies chitosan as 
a potent carrier for siRNA delivery, in vivo [152]. 
Conclusion 
Site-specific drug delivery is an important issue in cancer 
therapy because it can decrease drug toxicity and enhance 
therapeutic effects [29, 153]. The effective nanocarriers, 
which can be applied in cancer therapy should exhibit some 
features, including high biocompatibility and less toxicity, ef­
ficient drug loading, long-time circulation in bloodstream, and 
selective targeting of tumor cells [154, 155, 29, 156–160]. 
There are three main pathways by which NPs can be uptaken 
by cells, including endocytosis, phagocytosis, and receptor-
mediated endocytosis. In order to improve the internalization 
of NPs, their surface can be modified with some ligands that 
can selectively bind to their receptors on target cells. 
Regarding the high expression of FR on cancer cells and 
the lack of FR on normal cells, it seems that folate can be a 
potent targeting molecule that can be applied in NP-based 
cancer therapy [161]. Folate exhibits several properties such 
as possibility of conjugation, non-immunogenicity, and essen­
tial factor for tumor growth, which make it a novel targeting 
molecule for various tumors [162]. FA-targeted NPs can be 
also conjugated with some other targeting molecules that may 
enhance their cellular penetration. For example, trans-
activating transcriptional activator peptide (Tat) is a well-
known cell-penetrating peptide (CPP), which can enhance 
the efficient uptake of nanocarriers by target cells. Therefore, 
the combination of FR-mediated specificity and CPP­
mediated penetration may increase the efficiency of current 
FA-targeted nanocarriers for cancer therapy [163]. Dual 
targeting through FA and some anti-tumor antigen monoclo­
nal antibodies is another approach in improving tumor site-
specific cancer therapy. 
As discussed earlier, several FA-targeted NPs have suc­
cessfully been used for cancer therapy in vitro and in experi­
mental tumor models. Unfortunately, little is known regarding 
the efficiency of these FA-targeted NPs in human tumors, and 
this issue should be investigated in future studies. 
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